Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.410
+0.040 (2.92%)
At close: Apr 24, 2026, 4:00 PM EDT
1.350
-0.060 (-4.26%)
After-hours: Apr 24, 2026, 4:00 PM EDT
Innate Pharma Revenue
In the year 2025, Innate Pharma had annual revenue of 9.01M EUR, down -55.25%. Innate Pharma had revenue of 4.13M in the half year ending December 31, 2025, a decrease of -80.72%.
Revenue (ttm)
8.99M EUR
Revenue Growth
-55.29%
P/S Ratio
11.64
Revenue / Employee
51,678 EUR
Employees
174
Market Cap
123.03M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.01M | -11.12M | -55.25% |
| Dec 31, 2024 | 20.12M | -41.52M | -67.36% |
| Dec 31, 2023 | 61.64M | 3.97M | 6.88% |
| Dec 31, 2022 | 57.67M | 32.97M | 133.47% |
| Dec 31, 2021 | 24.70M | -45.07M | -64.60% |
| Dec 31, 2020 | 69.77M | -15.68M | -18.35% |
| Dec 31, 2019 | 85.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Verrica Pharmaceuticals | 35.58M |
| Pyxis Oncology | 13.86M |
| Cibus | 3.64M |
| Cardiff Oncology | 593.00K |
| NeOnc Technologies Holdings | 39.99K |
IPHA News
- 2 days ago - Innate Pharma SA: Innate Pharma to Participate in the D. Boral Capital Global Conference - Finanz Nachrichten
- 2 days ago - Innate Pharma to Participate in the D. Boral Capital Global Conference - Business Wire
- 8 days ago - Innate Pharma SA: Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026 - Finanz Nachrichten
- 8 days ago - Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026 - Business Wire
- 12 days ago - Innate Pharma SA: Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026 - Finanz Nachrichten
- 12 days ago - Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026 - Finanz Nachrichten
- 12 days ago - Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026 - Business Wire
- 12 days ago - Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026 - Business Wire